# Exercise and Inflammation in Coronary Artery Disease

1

Exercise and Inflammation in Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomised Trials.

Gareth Thompson<sup>1</sup>, Gareth W. Davison<sup>2</sup>, Jacqui Crawford<sup>1</sup>, and Ciara M. Hughes<sup>1</sup>.

<sup>1</sup> Institute of Nursing and Health Research, Ulster University, Jordanstown Campus, Shore Road, Newtownabbey, County Antrim, BT37 0QB, United Kingdom.

<sup>2</sup> Sport and Exercise Sciences Research Institute, Ulster University, Jordanstown Campus, Shore Road, Newtownabbey, County Antrim, BT37 0QB, United Kingdom.

Running heading: Exercise and Inflammation in Coronary Artery Disease

Word Count: 5393

**Corresponding Author** 

Name: Dr Ciara M. Hughes

Email address: cm.hughes@ulster.ac.uk

Contact number: +44 28 9036 6227

ORCID

Mr Gareth Thompson: 0000-0002-4658-8132

Dr Ciara M. Hughes: 0000-0002-1064-6775

Mrs Jacqui Crawford: 0000-0001-7656-9613

Professor Gareth W. Davison: 0000-0002-2002-2253

# Abstract

Current evidence suggests that chronic inflammation contributes to the development and progression of coronary artery disease (CAD). Interestingly, exercise may constitute a method of reducing inflammation in this patient population. As such, this systematic review and meta-analysis examined the evidence generated by randomised studies that investigated the effect of exercise on inflammatory biomarkers in CAD. Literature was sought from various sources. Outcomes were pooled in a random-effects model to calculate standardised mean differences (SMD) with 95% confidence intervals (CI). Twenty-five studies were reviewed; post-intervention C-reactive protein (SMD: -0.55 (95% CI: -0.93, -0.16), P= 0.005), fibrinogen (SMD: -0.52 (95% CI: -0.74, -0.29, P= <0.00001), and von Willebrand factor (SMD: -1.57 (95% CI: -2.23, -0.92), P= <0.00001) values were significantly lower in exercise groups compared to controls. In addition, qualitative analyses identified evidence that supports a beneficial effect of exercise on these acute-phase reactants. However, the impact of exercise on anti-inflammatory cytokines, adhesion molecules, and chemokines is equivocal, which may be attributed to a paucity of research. Nevertheless, the findings of this review suggest that exercise induces an anti-inflammatory effect in CAD patients. Although, the quality of evidence needs to be improved by further randomised studies with high methodological qualities and large sample sizes.

KEYWORDS: Exercise, inflammation, coronary artery disease, systematic review, meta-analysis

Coronary artery disease (CAD) involves an attenuation of myocardial perfusion due to progressive intraluminal accumulation of fibrous atherosclerotic plaque within an epicardial coronary artery (1). The ramifications of this may include: acute coronary syndrome comprising myocardial infarction and angina pectoris, impaired ventricular function, or heart failure (2,3). Despite improvements in cardiovascular disease (CVD) science and medical care over the past few decades, CAD remains a leading cause of mortality throughout the world (4).

The global prevalence of CAD has provoked scientific investigations to elucidate the underlying pathophysiological mechanisms responsible for atherogenesis. As a consequence, it is becoming increasingly clear that low-grade chronic inflammation is implicated in each pathological stage of atherosclerotic development (5,6). Notably, Ridker et al. (7) recently documented that the administration of canakinumab, a monoclonal antibody that targets the interleukin-1 beta innate immunity pathway, contributed to a significant reduction in high sensitivity C-reactive protein (hs-CRP) and recurrent cardiovascular complications in CAD patients with previous myocardial infarction and a residual inflammatory response (hs-CRP > 2 milligrams per litre) compared to placebo. Therefore, this investigation provided evidence of the benefits of targeting inflammatory pathways to improve clinical outcomes in high-risk CAD patients.

Exercise is an established therapeutic strategy for primary and secondary prevention of CAD (8-11). Interestingly, a meta-analysis performed by Swardfager et al. (12) concluded that exercise may reduce inflammatory activity in CAD patients, as indicated by lower post-intervention values of C-reactive protein (CRP), fibrinogen, interleukin-6 (IL-6), and vascular cell adhesion molecule-1 (VCAM-1). As such, this conclusion suggests that exercise may induce an anti-inflammatory effect in CAD patients, which may partially represent a mechanism by which secondary prevention is conferred. However, the evidence produced by Swardfager et al. (12) was generated by pooling randomised and non-randomised studies; the latter study design potentially decreasing the validity of the results due to selection bias (13). As such, this systematic review and meta-analysis will analyse randomised studies that investigated the effect of exercise on inflammatory biomarkers in CAD patients. Utilising this approach will provide a timely update to the evidence base by synthesising a rigorous examination of the capability of exercise to serve as an anti-inflammatory strategy in CAD.

# Methods

The methodology implemented in this systematic review and meta-analysis adhered to guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions (14), and the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) recommendations (15) (PROSPERO registration number: CRD42018105245).

# Search Strategy

A computerised search of the following databases from inception to August 2019 was performed: MEDLINE, EMBASE, AMED, CINAHL, Cochrane Central Register of Controlled Trials, and SPORT Discus. To ensure a comprehensive search strategy was implemented, various search terms comprising Medical Subject Headings

(MeSH), database specific subject headings, and key words were derived from four primary concepts: "coronary artery disease", "exercise", "inflammatory biomarker", and "randomised trial". The search strategy was limited to human trials and English publications. An example of the implemented search strategy for Cochrane Central Register of Controlled Trials is presented in Electronic Supplementary Material (ESM) 1, Appendix S1. To minimise the risk of introducing bias to this review, grey literature was sought from the following resources: Google Scholar, specialised databases (National Rehabilitation Information Centre, Physiotherapy Evidence Database, and the National Institute for Health Research Journals Library), and the International Clinical Trials Registry Platform. Hand searching of reference lists of articles and previous reviews was also performed to identify additional trials that were potentially eligible. All identified publications were read as either abstracts or full texts.

#### **Inclusion and Exclusion Criteria**

A protocol comprising inclusion and exclusion criteria was established to ascertain suitable studies for inclusion (see Table 1).

#### **Data Extraction**

Data not reported in main text or tables were extracted from figures when possible. If available, data analysed using the intention-to-treat principles were preferentially extracted to mitigate bias and permit clinical relevance (16). When insufficient information was reported by a study, a member of the review team (Mr Gareth Thompson (GT)) contacted the authors to request any missing data. Two members of the review team (GT and Dr Ciara M. Hughes (CMH)) independently extracted the necessary data from each included study into a preformatted data collection form designed by the Cochrane Collaboration. Discrepancies were identified and discussed until disagreements were resolved by consensus (a third member of the review team (Mrs Jacqui Crawford (JC) was consulted when necessary). The lead review author (GT) entered the data into tables and inserted a unified data set into Review Manager Version 5.3 for the completion of meta-analyses.

#### **Quality Assessment**

The reliability of the results provided by each trial was determined by conducting a risk of bias (ROB) assessment in accordance with guidelines presented in the Cochrane Handbook for Systematic Reviews of Interventions (16). In accordance with Sveaas et al. (17), the "blinding of participants and personnel" ROB item was excluded as such an approach is very difficult, if not impossible to utilise in studies that implemented an exercise intervention. When available, published *a priori* study protocols were used to supplement the assessment of ROB.

The quality of evidence for each outcome that was included in the post-intervention inflammatory biomarker value comparisons between exercise and control groups was rated in accordance with the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system (18) (see Table 2). Three members (GT, CMH, and JC) of the review team independently performed a ROB and GRADE assessment on the included studies to mitigate the influence of individual subjectivity during quality assessment; disagreements were discussed at a meeting until the final decisions were agreed by consensus.

#### **Statistical Analysis**

A random-effects inverse variance model was used to calculate standardised mean differences (SMD) with 95% confidence intervals (CIs). In accordance with Swardfager et al. (12), meta-analyses were conducted to facilitate post-intervention value comparisons between exercise and control groups (a negative SMD represents a lower value in the exercise group compared to control group). A random-effects inverse variance model was chosen due to anticipated clinical heterogeneity between studies, and SMD was calculated due to expected variance in outcome measurement methodology (19). An SMD  $\leq 0.4$  was interpreted as a small effect size, between 0.5 and 0.7 was considered to be a medium effect size, and  $\geq 0.8$  was deemed a large effect size (20). Data were pooled for meta-analyses when  $\geq$  two studies measured the same outcome and data was available in a suitable format (mean ± standard deviation (SD)). If studies reported data as median and range or interquartile range (IQR), the sample means  $\pm$  SDs were estimated by utilising the formula proposed by Wan et al. (21). Further, if mean  $\pm$ standard error of the mean (SEM) was reported, the Review Manager Version 5.3 calculator resource was used to estimate SD. When a study implemented multiple exercise groups, the data for each group was entered separately as an independent data point. Additionally, the sample size of the control group was divided by the number of intervention groups to prevent a unit of analysis error (19). A P value of  $\leq 0.05$  was considered statistically significant. Heterogeneity was investigated through inspection of I<sup>2</sup> and  $\chi^2$  test values; a P value of  $\leq 0.1$  for the  $\chi^2$  test or an I<sup>2</sup> value of  $\geq$  50% was considered to be indicative of substantial heterogeneity (22). Sub-group analyses were performed using  $\chi^2$  heterogeneity statistics to investigate if the following variables influenced the magnitude of effect (SMD) or contributed to heterogeneity in the overall pooled results:

- Duration of exercise programme: < 12-weeks versus  $\ge 12$ -weeks.
- Sessions per week:  $\leq 3$  compared to > 3.
- Exercise modality: aerobic interval exercise (AIE) versus continuous aerobic exercise (CAE) versus resistance training (RT) verses a combination of RT and cardiorespiratory exercise (AIE or CAE).
- Exercise alongside cardiac rehabilitation (CR) versus exercise only.

A statistically significant test for sub-group differences was considered as  $P \le 0.1 (\chi^2)$  (19). Sensitivity analyses were performed to assess the robustness of the pooled results by removing the studies that reported data that required the estimation of mean ± SD from median and range or IQR, or SD from the SEM. Additionally, the influence of "outlying" data generated by one study (23) on the results of the post-intervention CRP value comparison was investigated. All meta-analyses were performed using Review Manager Version 5.3. Descriptive analyses were performed for studies and outcomes that could not be meta-analysed.

#### Results

#### **Study Selection**

A total of 8,290 articles were identified by various literature searches. The lead author (GT) performed the initial screening process, which entailed reading the titles and abstracts of articles to exclude irrelevant studies that did

not meet the inclusion criteria. Following the initial screening process, a full text evaluation of thirty-three articles was independently performed by three members (GT, CMH, and JC) of the review team to ascertain correlation with the inclusion criteria. Authors were contacted if any uncertainty existed surrounding the suitability of a particular study for inclusion. If no reply was provided, the study was excluded. A meeting was held between the three members (GT, CMH, and JC) of the review team to discuss findings, until disagreements were agreed by consensus. Consequently, twenty-five randomised studies (23-47) were deemed appropriate for inclusion in this systematic review; ten (24,26,28,29,33,35,36,41,44,46) of which were unsuitable for meta-analyses (see Figure 1

#### **Study Characteristics**

for PRISMA flow diagram depicting the study selection process).

The main study characteristics are presented in ESM 1, Tables S1, S2, S3, and S4. Studies were published between 2006 and 2017. Of the twenty-five randomised studies that were included, eighteen trials (23,25,27,30-32,34,36-40,42-47) randomised participants to an exercise intervention or control group, three studies (26,28,33) randomised participants to different forms of exercise, one study (35) randomised participants to an exercise intervention or low-energy diet, two studies (24,29) randomised participants to different forms of CR, and one study (41) randomised participants to a combination of exercise and a standard dose of rosuvastatin or atorvastatin treatment.

#### **Participant Characteristics**

Sample populations in the twenty-five included studies varied from 28 to 275 participants. Overall, the included studies provided results for 2105 (1426 exercising and 679 control) participants, of which, 73% were male (1527). The mean age of the participants was  $59.9 \pm 4.2$  years (range: 51-68 years). The condition of CAD in the included participants encompassed: post- revascularisation (coronary artery bypass graft/ percutaneous coronary intervention), post-myocardial infarction, stable angina pectoris, and  $\geq 3$  months after cardiovascular complication or revascularisation. Finally, participant baseline inflammatory biomarker concentrations varied from low to high across the included studies (see ESM 1, Tables S5.1 and S5.2 for participant baseline inflammatory biomarker concentrations).

# **Exercise Intervention Characteristics**

A detailed description of the exercise intervention characteristics can be found in ESM 1, Tables S1, S2, S3, and S4. Each of the included studies implemented a cardiorespiratory (CAE and/ or AIE) intervention. Moreover, six of the included studies (24,28,29,40,42,44) implemented a group that received a RT intervention alone or in combination with cardiorespiratory exercise. Across which, the utilised RT exercises (weights, resistance bands, resistance machines, and wall-pulleys) activated major muscle groups (upper and/ or lower body).

According to exercise intensity classifications published by the American College of Sports Medicine (48), eighteen of the included studies (23,25-30,32-35,38,40,42-46) prescribed a vigorous intensity for the cardiorespiratory exercise intervention, and the remaining seven studies (24,31,36,37,39,41,47) prescribed a

moderate intensity. The prescribed RT intensity across two studies (28,40) ranged from 60-65% of one-repetition maximum. Furthermore, one study (42) prescribed a RT intensity of 60% of maximum voluntary contraction, one study (44) described the RT intensity as being similar to that of the accompanying vigorous intensity cardiorespiratory exercise, and two studies (24,29) did not report the prescribed RT intensity. Overall, mean exercise session duration was  $38 \pm 12$  minutes (range: 15-75 minutes); mean exercise session frequency was  $4 \pm 1$  sessions per week (range: 2-7 sessions per week); and mean exercise intervention period was  $14 \pm 10$  weeks (range: 3-48 weeks).

# Synthesis of Results

Ten studies were not included in any of the meta-analyses performed; seven of which did not implement a control group (24,26,28,29,33,35,41), El Missiri and Taher (46) reported a baseline imbalance in CRP values, Luk et al. (44) presented data in an inappropriate format (mean change  $\pm$  SD), and Raygan et al. (36) was the only study to report data for interleukin-33 (IL-33) and interleukin-35 (IL-35). Moreover, Oliveira et al. (34) was excluded from the post-intervention CRP value comparison due to a baseline imbalance in CRP concentrations. Summaries of the various meta-analyses that were performed are provided in ESM 2, Table S1.

#### **Post-Intervention Inflammatory Biomarker Comparisons**

The results of the post-intervention inflammatory biomarker comparisons between exercise and control groups are depicted in Figures 2.1, 2.2, 2.3, and 3. Very low qualities of evidence for significant medium and large beneficial effect sizes for exercise on CRP (SMD: -0.55 (95% CI: -0.93, -0.16), P= 0.005), fibrinogen (SMD: -0.52 (95% CI: -0.74, -0.29, P= <0.00001), and von Willebrand factor (vWF) (SMD: -1.57 (95% CI: -2.23, -0.92), P= <0.00001) were documented. However, between-study heterogeneity was substantial for CRP (I<sup>2</sup>= 85%,  $\chi^2$  P= <0.00001) and vWF (I<sup>2</sup>= 76%,  $\chi^2$  P= 0.007). Significant effect sizes were not documented for IL-6, interleukin-10 (IL-10), tumour necrosis factor-alpha (TNF- $\alpha$ ), VCAM-1, intercellular adhesion molecule-1 (ICAM-1), E-selectin, interleukin-8 (IL-8), and regulated on activation, normal T-cell expressed and secreted (RANTES).

#### **Descriptive Analyses**

A summary of the results for each of the included studies is presented in ESM 1, Tables S1, S2, S3, and S4. Across the outcomes that could not be meta-analysed, beneficial within-exercise group changes were demonstrated for soluble tumour necrosis factor- alpha receptor 1 (TNF- $\alpha$  SR1) (P< 0.001) (47), chemokine (C-C motif) ligand 21 (CCL21) (P< 0.05) (43), and IL-35 (P= 0.001) (36). Also, positive differences between exercise and control groups were observed for TNF- $\alpha$  SR1 (P= 0.004) (47), IL-35 (P= 0.002) (36) and interferon gamma-induced protein 10 (IP-10) (P= 0.03) (27). No significant changes were reported within or between-groups for IL-33 (36), monokine induced by gamma interferon (Mig) (27), monocyte chemoattractant protein 1 (MCP-1) (43), chemokine (C-C motif) ligand 19 (CCL19) (43), chemokine (C-X-C motif) ligand 16 (CXCL16) (43), CD40 ligand (CD40L) (43), and pentraxin 3 (PTX-3) (43).

In terms of the studies that were not included in the meta-analyses, eight trials (26,28,29,33,35,41,44,46) investigated the impact of exercise on CRP. Across which, beneficial within-exercise group changes were observed by four studies (26,29,41,46), whilst no significant changes were reported by the other four studies (28,33,35,44). Three trials (28,29,35) examined the effect of exercise on IL-6; one study (29) documented beneficial within-exercise group changes, whilst the remaining two studies (28,35) observed no significant changes. Two studies (29,35) reported data regarding the influence of exercise on TNF- $\alpha$ . Beneficial within-exercise group changes were observed by one study (29), whereas the other trial documented no significant changes (35). Finally, beneficial within-exercise group changes were observed for ICAM-1 (29), fibrinogen (24), and vWF (24), whilst no significant changes were observed for IL-8 (28) or P-selectin (24).

# **Quality Assessment**

A summary of the ROB assessment for the twenty-five included studies is presented in Figure 4. Three studies (24,33,35) were rated as a low risk of bias for each domain. However, inadequate reporting of random sequence generation and allocation concealment decreased the reliability of the results across most of the included studies. The results for the quality of evidence assessment using the GRADE system are presented in ESM 2, Table S2. Issues pertaining to the before mentioned ROB study limitations, along with inconsistency of results, indirectness of evidence, and imprecision resulted in the overall quality of evidence ranging from very low to moderate for the inflammatory biomarkers included in the post-intervention value comparisons.

#### **Sub-group Analyses**

The results of the sub-group analyses are presented in ESM 3, Tables S1, S2, S3, and S4. Various statistically significant ( $\chi^2 P \le 0.1$ ) sub-group differences were detected (see ESM 4, Table S1 for summaries of the statistically significant sub-group differences). However, an uneven covariate (a limited or unbalanced number of studies and / or participants contributing to each sub-group) distribution rendered the results meaningless (49). As such, the results of the statistically significant sub-group differences were not discussed in order to circumvent misleading conclusions.

# Sensitivity Analyses

The results of the sensitivity analyses are presented in ESM 4, Tables S2 and S3. Removal of the six studies (27,34,37,38,40,47) that presented data that necessitated the estimation of mean  $\pm$  SD or SD from the corresponding meta-analyses precluded post-intervention value comparisons for IL-8, IL-10, TNF- $\alpha$ , P-selectin, and RANTES as < 2 studies were available for pooling. As such, the results of these meta-analyses should be interpreted with caution. Nevertheless, of the sensitivity analyses that could be performed, the results indicated that the inclusion of data that required the estimation of mean  $\pm$  SD or SD did not substantially influence the directions and significance levels of the effect sizes, or substantially increase the between-study heterogeneity across the CRP, IL-6, and VCAM-1 meta-analyses (see ESM 4, Table S2). However, the removal of data that required the estimation of mean  $\pm$  SD or SD resulted in significant medium beneficial effect sizes for exercise on

8

ICAM-1 (before; SMD: -0.35 (95% CI: -0.72, 0.01), P= 0.06, after; SMD: -0.77 (95% CI: -1.23, -0.31), P= 0.001) and E-selectin (before; SMD: -0.31 (95% CI: -0.66, 0.05), P= 0.09, after; SMD: -0.57 (95% CI: -1.03, -0.11), P= 0.01). Moreover, the between-study heterogeneity was reduced for ICAM-1 (before: I<sup>2</sup>= 58%,  $\chi^2$  P= 0.07, after: I<sup>2</sup>= 0%,  $\chi^2$  P= 0.61) and E-selectin (before: I<sup>2</sup>= 35%,  $\chi^2$  P= 0.22, after: I<sup>2</sup>= 0%,  $\chi^2$  P= 0.85). Nonetheless, these results should be interpreted with caution due to the small sample sizes of the meta-analyses (ICAM: 40 exercise participants and 38 controls, E-selectin: 38 exercise participants and 38 controls).

The study performed by Giallauria et al. (23) generated a noticeably larger beneficial effect size in comparison to the other pooled studies in the post-intervention CRP value comparison. Therefore, a sensitivity analysis was performed to ascertain the influence of this "outlying" data on the overall pooled results by removing Giallauria et al. (23). Consequently, no major impact on the direction and significance level of the pooled effect size, or substantial change in between-study heterogeneity was documented (see ESM 4, Table S3).

#### Adverse Events, Withdrawals, and Exercise Session Compliance

A detailed report of adverse events, withdrawals, and exercise session compliance can be found in ESM 4, Table S4). Fourteen of the included studies (23,25,26,28,32-35,37,38,40,42,43,47) reported on adverse events. Exercise was safe; no adverse events during or as a result of exercise were reported. Across the included studies, the mean withdrawal rate was 5% (range: 0-22%). Information regarding participant compliance with the prescribed exercise sessions was reported by thirteen studies (23,26,28,29,31-35,37,42-44). On average, the participants across these studies completed 88% (range: 60-100%) of the prescribed exercise sessions.

#### Discussion

The contribution of chronic inflammation to the development and progression of CAD is now well established (5,6). Interestingly, there is evidence to suggest that exercise may constitute a method of reducing inflammatory activity in this patient population (12), which potentially partially explains the secondary prevention induced by this intervention. As such, the purpose of this systematic review and meta-analysis was to provide a timely update to the literature by rigorously examining the influence of exercise on various inflammatory biomarkers in CAD patients.

Twenty-five randomised studies comprising 2105 (1426 exercising and 679 controls) participants were reviewed. Saliently, an anti-inflammatory effect of exercise was documented, as indicated by significant beneficial effects on CRP, fibrinogen, and vWF. Moreover, the meta-analyses of inflammatory biomarkers that documented non-significant results generated SMDs that represented lower post-intervention values in the exercise groups compared to controls. Failure to reach significance for these inflammatory biomarker outcomes could be a result of wide confidence intervals due to small sample sizes.

The anti-inflammatory effects of exercise in CAD patients, as documented in this review, may lack generalisability in healthy populations. In particular, there is inconsistent evidence for an anti-inflammatory effect

of exercise in healthy populations (50-54). Therefore, the discrepancy between the results of this review and the evidence for an anti-inflammatory effect in healthy populations may be attributed to a more pronounced effect in CAD patients due to higher baseline levels of inflammatory activity (55), or an amelioration of principal CVD risk factors that promote inflammation, such as: dyslipidaemia, hypertension, diabetes, and obesity (56,57). Whilst it was beyond the scope of this review to investigate these relationships, Swardfager et al. (12) reported that elevated baseline CRP values and adverse lipid profiles were associated with greater reductions in CRP values in CAD patients. Moreover, a recent meta-analysis performed by Fedewa et al. (54) demonstrated that exercise induced greater reductions in CRP when accompanied by a decrease in body mass index in healthy and clinical populations. Besides improving CVD risk factors, exercise may also incite anti-inflammatory protection by directly modulating various overlapping signalling pathways associated with oxidative stress and inflammation (58). However, the influence of exercise on these underlying mechanisms is poorly understood (58), and is an area for future research.

#### **Pro-inflammatory Cytokines**

In accordance with the results of the meta-analysis performed by Swardfager et al. (12), the post-intervention IL-6 and TNF- $\alpha$  value comparisons between exercise and control groups were not significantly different. Although, the paucity of data from studies that implemented a control group may account for these non-significant findings. Regarding the studies that were not included in the meta-analyses, the evidence for a beneficial effect of exercise on pro-inflammatory cytokines was inconsistent. To elaborate, one study (29) documented beneficial within-exercise group changes in IL-6 and TNF- $\alpha$ , whilst two studies reported no significant changes (28,35). However, the trials performed by Hansen et al. (28) and Pedersen et al. (35) may have been underpowered to detect changes in IL-6 or TNF- $\alpha$  as sample size calculations based on pro-inflammatory cytokines were not performed. When considering the individual results of the included studies, Schumacher et al. (38) recorded a significant inverse correlation between physical performance and levels of IL-6. Moreover, Munk et al. (43) observed positive differences between exercise and control groups in IL-6, and Balen et al. (47) documented beneficial differences between exercise and control groups in TNF- $\alpha$  SR1. As such, these findings potentially represent a positive effect of exercise on pro-inflammatory cytokines. Nevertheless, the results of this review failed to generate conclusive evidence that exercise significantly reduces pro-inflammatory cytokines. Therefore, further research regarding the effect of exercise on these inflammatory mediators is required.

#### **Anti-inflammatory Cytokines**

The meta-analyses performed in this review failed to demonstrate a beneficial effect of exercise on IL-10 concentrations, which may be attributed to the small number of pooled studies. Overall, the individual results of four (36,37,43,47) out of the five studies (34,36,37,43,47) that examined the effect of exercise on anti-inflammatory cytokines documented positive influences. Nevertheless, the paucity of evidence in this area precluded a robust evaluation. As such, further research into the effect of exercise on anti-inflammatory cytokines in CAD patients is required.

#### **Acute-phase Reactants**

The results of this review documented a positive influence of exercise on acute-phase reactants; post-intervention CRP, fibrinogen, and vWF value comparisons documented very low qualities of evidence for significantly lower values in exercise groups compared to controls. However, the results of the CRP and vWF meta-analyses should be interpreted with caution as substantial between-study heterogeneity was identified. Moreover, the post-intervention vWF value comparison comprised two studies, which limits the validity of the result. Qualitatively, the findings of the trials that were not included in the meta-analyses support the quantitative results of this review; five (24,26,29,41,46) out of the nine studies (24,26,28,29,33,35,41,44,46) that investigated the impact of exercise on acute-phase reactants reported beneficial within-exercise group changes. Altogether, the results of this review support the ability of exercise to reduce CRP, fibrinogen, and vWF in CAD patients. The correlation between these acute-phase reactants and adverse outcomes accentuates the potential importance of this finding (59-63).

#### **Adhesion Molecules**

The meta-analyses failed to find significant post-intervention differences between exercise and control groups for VCAM-1, ICAM-1, P-selectin and E-selectin. Although, a positive effect of exercise on ICAM-1 approached statistical significance (P=0.06). When considering the results of the studies individually, only three (29,38,45) of the eight studies (24,27,29,34,37,38,43,45) that investigated the effect of exercise on adhesion molecules demonstrated a significant effect. However, two of these studies (29,38) provided an exercise intervention alongside a comprehensive CR programme, which limits attributing these results to an independent effect of exercise. With regard to Ribeiro et al. (37), no significant within-exercise group changes in the post-intervention levels of ICAM-1 and VCAM-1 were documented. Yet, the post-intervention values of these adhesion molecules significantly increased in the control group, which resulted in significant between-group differences for changes in ICAM-1 and VCAM-1 levels. Interestingly, these results imply that exercise may supress deterioration in endothelial function. Collectively, the results of this review failed to demonstrate conclusive evidence for a beneficial effect of exercise on adhesion molecules. Nevertheless, the majority of studies possessed small sample sizes, which may account for the non-significant results. Also, the limited data for each adhesion molecule precluded a robust evaluation. Despite the equivocal effect of exercise on adhesion molecules, six studies (24,26,33,39,42,44) in this review demonstrated an improvement in endothelial function as measured via brachial flow mediated dilatation (FMD). The ability of exercise to stimulate an improvement in brachial FMD was also supported by a recent meta-analysis (64). As such, studies should continue to explore the effect of exercise on adhesion molecules to further illuminate the exercise induced improvements in endothelial function.

#### Chemokines

The meta-analyses failed to find significant post-intervention differences between exercise and control groups for IL-8 and RANTES, which may be attributed to the small number of pooled studies. In terms of the qualitative analysis, the effect of exercise on chemokines was equivocal. To elaborate, across the included studies, no significant effects on post-intervention values of Mig, RANTES, CXCL16, CCL19, MCP-1, and CD40L were

documented. However, two (43,47) out of the three studies (28,43,47) that evaluated the impact of exercise on IL-8 observed significantly lower post-intervention values in exercise groups compared to controls. Moreover, Fernandes et al. (27) demonstrated beneficial between-group differences in post-intervention IP-10 values, and Munk et al. (43) recorded significant within-exercise group reductions in CCL21 levels. In particular, the results generated by Fernandes et al. (27) are of interest as there is evidence to suggest that increased levels of IP-10 correlate with restenosis following PCI in CAD patients (65). Overall, the limited amount of evidence for the effect of exercise on chemokines prevented a valid evaluation. Moreover, the reviewed studies consisted of small sample sizes, which as mentioned before, may have precluded the identification of significant results. Given the vital role of chemokines in orchestrating atherogenesis (66), and in acknowledgment of the qualitative findings, further research into the effect of exercise on chemokines is required.

# **Sub-group Analyses**

An uneven covariate distribution precluded valid sub-group analyses of the influence of exercise intervention characteristics on inflammatory biomarker changes. However, six of the included studies (24,26,28,33,40,42) compared the effects of different exercise modalities on inflammatory biomarkers. Across which, no statistically significant between-exercise group differences in post-intervention inflammatory biomarker values were seen.

The acute response to exercise involves the release of IL-6 from skeletal muscle cells, which serves as a stimulus for anti-inflammatory adaptation (57). Importantly, the intensity (67) and duration of exercise (57), along with the involved muscle mass (57,68) determine the acute rise in IL-6. However, evidence regarding optimal exercise characteristics for inducing anti-inflammatory protection is equivocal. To elaborate, Hayashino et al. (69) stated that longer exercise programmes and greater exercise session frequencies were associated with greater reductions in IL-6, albeit results from type 2 diabetes patients. In contrast, Swardfager et al. (12) demonstrated that the duration of exercise programmes was not associated with a decrease in CRP in CAD patients. Moreover, Fedewa et al. (54) concluded that duration, frequency, and mode of exercise were not associated with reductions in CRP in healthy and clinical populations. As such, further research to identify optimal exercise characteristics for reducing inflammation in CAD patients is necessary.

# **Strengths and Limitations**

To our combined knowledge, this is the first systematic review and meta-analysis to exclusively evaluate randomised studies that investigated the effect of exercise on inflammatory biomarkers in CAD patients. The exclusion of studies that possessed confounding variables, such as: the recruitment of CAD patients with severe heart failure (New York Heart Association (NYHA) Class III or IV or left ventricular ejection fraction (LVEF)  $\leq$  30%), or the provision of co-interventions (e.g. a hypocaloric diet or antioxidant/ vitamin supplement) to exercise increased the validity of the findings. Further strengths of this review include: a comprehensive literature search, evaluation of overall quality of evidence using the GRADE system, and the pooling of data for meta-analyses. Moreover, qualitative analyses of studies and outcomes that could not be meta-analysed were performed to circumvent the exclusion of valuable findings.

The exclusion of studies that recruited patients with severe heart failure (NYHA Class III or IV or LVEF  $\leq$  30%) limits extrapolating the results of this review to CAD patients with these deteriorated conditions. Whilst a comprehensive literature search was performed, the exclusion of studies that were not reported in English may have introduced publication bias. Nevertheless, this issue was not strongly suspected for any outcome as both negative and positive findings were reported by studies with varying sample sizes.

A further limitation involves the sub-group analyses of exercise intervention characteristics failing to provide a valid evaluation of potential sources of between-study heterogeneity. However, the level of between-study heterogeneity may also have been influenced by the following factors: population characteristics (i.e. comorbidities) (56), diet (70), medication (71), natural recovery following cardiovascular complication/ surgical intervention (72,73), measurement medium (plasma or serum) (74), and methods employed for blood sample preparation and handling (74-76).

With regard to study quality, inadequate reporting of random sequence generation and allocation concealment, along with imprecision as a result of small sample sizes decreased the reliability of the results across most of the included studies and limited the overall quality of evidence. As such, the results of this review should be interpreted with caution until further randomised studies with high methodological qualities and large sample sizes are conducted.

#### Conclusion

This systematic review and meta-analysis demonstrates that exercise reduces CRP, fibrinogen, and vWF concentrations in CAD patients. In addition, qualitative analyses identified evidence that supports a positive effect on these acute-phase reactants. However, current evidence surrounding the effect of exercise on anti-inflammatory cytokines, adhesion molecules, and chemokines is equivocal, which may be attributed to a paucity of research. Nevertheless, whilst the findings of this review support the ability of exercise to reduce inflammatory activity in CAD patients, various requirements for future research have been identified. Firstly, the quality of evidence for this area needs to be improved by further randomised studies with high methodological qualities and large sample sizes. Moreover, additional research into the effect of exercise to be utilised as an anti-inflammatory strategy in CAD, future studies should seek to identify optimal exercise characteristics for mitigating inflammation. Finally, to generate a comprehensive understanding of the anti-inflammatory effect of exercise, future research should explore the underlying molecular mechanisms that may be responsible for orchestrating an exercise induced reduction in inflammation.

# **Funding details**

This work was supported by the Department for the Economy Award.

# **Disclosure of interest**

The authors report no conflict of interest.

# Data availability statement

The authors confirm that the data supporting the findings of this systematic review and meta-analysis are available within the article and its supplementary materials.

#### References

(1) Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-3488.

(2) Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138.

(3) Santos-Gallego CG, Picatoste B, Badimón JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep. 2014;16(4):401.

(4) Wang H, Naghavi M, Allen C, Barber R, Carter A, Casey D, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016;388(10053):1459-1544.

(5) Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-2051.

(6) Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012;28(6):631-641.

(7) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.

(8) Haskell WL, Lee I, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116(9):1081.

(9) Anderson L, Oldridge N, Thompson DR, Zwisler A, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67(1):1-12.

(10) Alves AJ, Viana JL, Cavalcante SL, Oliveira NL, Duarte JA, Mota J, et al. Physical activity in primary and secondary prevention of cardiovascular disease: Overview updated. World J Cardiol. 2016;8(10):575-583.

(11) Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381.

(12) Swardfager W, Herrmann N, Cornish S, Mazereeuw G, Marzolini S, Sham L, et al. Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis. Am Heart J. 2012;163(4):666-676.

(13) Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration;2011. Available from: www.handbook.cochrane.org

(14) Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration;2011. Available from: <u>www.handbook.cochrane.org</u>

(15) Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6(7):e1000097.

(16) Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration;2011. Available from <a href="http://www.handbook.cochrane.org">www.handbook.cochrane.org</a>

(17) Sveaas SH, Smedslund G, Hagen KB, Dagfinrud H. Effect of cardiorespiratory and strength exercises on disease activity in patients with inflammatory rheumatic diseases: a systematic review and meta-analysis. Br J Sports Med. 2017;51(14):1065-1072.

(18) Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406.

(19) Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration;2011. Available from <u>www.handbook.cochrane.org</u>

(20) Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Routledge;1988.

(21) Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology. 2014;14(1):135.

(22) Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.

(23) Giallauria F, Cirillo P, D'agostino M, Petrillo G, Vitelli A, Pacileo M, et al. Effects of exercise training on high-mobility group box-1 levels after acute myocardial infarction. J Card Fail. 2011;17(2):108-114.

(24) Lee KW, Blann AD, Jolly K, Lip GY, BRUM Investigators. Plasma haemostatic markers, endothelial function and ambulatory blood pressure changes with home versus hospital cardiac rehabilitation: the Birmingham Rehabilitation Uptake Maximisation Study. Heart. 2006;92(12):1732-1738.

(25) Bilinska M, Kosydar-Piechna M, Gasiorowska A, Mikulski T, Piotrowski W, Nazar K, et al. Influence of dynamic training on hemodynamic, neurohormonal responses to static exercise and on inflammatory markers in patients after coronary artery bypass grafting. Circulation Journal. 2010;74(12):2598-2604.

(26) Conraads VM, Pattyn N, De Maeyer C, Beckers PJ, Coeckelberghs E, Cornelissen VA, et al. Aerobic interval training and continuous training equally improve aerobic exercise capacity in patients with coronary artery disease: the SAINTEX-CAD study. Int J Cardiol. 2015;179:203-210.

(27) Fernandes JL, Serrano CV, Toledo F, Hunziker MF, Zamperini A, Teo FH, et al. Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease. Clinical Research in Cardiology. 2011;100(1):77-84.

(28) Hansen D, Eijnde BO, Roelants M, Broekmans T, Rummens J, Hensen K, et al. Clinical benefits of the addition of lower extremity low-intensity resistance muscle training to early aerobic endurance training intervention in patients with coronary artery disease: a randomized controlled trial. J Rehabil Med. 2011;43(9):800-807.

(29) Beckie TM, Beckstead JW, Groer MW. The influence of cardiac rehabilitation on inflammation and metabolic syndrome in women with coronary heart disease. J Cardiovasc Nurs. 2010;25(1):52-60.

(30) Lee Y, Jun I, Ju S. Impact of Home Exercise Training on Patientswith Acute Myocardial Infarction. Journal of Physical Therapy Science. 2012;24(8):743-745.

(31) Lian X, Zhao D, Zhu M, Wang Z, Gao W, Zhao H, et al. The influence of regular walking at different times of day on blood lipids and inflammatory markers in sedentary patients with coronary artery disease. Prev Med. 2014;58:64-69.

(32) Madssen E, Arbo I, Granøien I, Walderhaug L, Moholdt T. Peak oxygen uptake after cardiac rehabilitation: a randomized controlled trial of a 12-month maintenance program versus usual care. PLoS One. 2014;9(9):e107924.

(33) Moholdt T, Aamot IL, Granøien I, Gjerde L, Myklebust G, Walderhaug L, et al. Aerobic interval training increases peak oxygen uptake more than usual care exercise training in myocardial infarction patients: a randomized controlled study. Clin Rehabil. 2012;26(1):33-44.

(34) Oliveira NL, Ribeiro F, Silva G, Alves AJ, Silva N, Guimarães JT, et al. Effect of exercise-based cardiac rehabilitation on arterial stiffness and inflammatory and endothelial dysfunction biomarkers: a randomized controlled trial of myocardial infarction patients. Atherosclerosis. 2015;239(1):150-157.

(35) Pedersen LR, Olsen RH, Anholm C, Walzem RL, Fenger M, Eugen-Olsen J, et al. Weight loss is superior to exercise in improving the atherogenic lipid profile in a sedentary, overweight population with stable coronary artery disease: A randomized trial. Atherosclerosis. 2016;246:221-228.

(36) Raygan F, Sayyah M, Qamsari, Seyed Mohammad Reza Janesar, Nikoueinejad H, Sehat M. Effects of submaximal aerobic exercise on regulatory T cell markers of male patients suffering from ischemic heart disease. Iranian Journal of Allergy, Asthma and Immunology. 2017;16(1):14-20.

(37) Ribeiro F, Alves A, Teixeira M, Miranda F, Azevedo C, Duarte J, et al. Exercise training increases interleukin-10 after an acute myocardial infarction: a randomised clinical trial. Int J Sports Med. 2012;33(03):192-198.

(38) Schumacher A, Peersen K, Sommervoll L, Seljeflot I, Arnesen H, Otterstad JE. Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease. European Journal of Cardiovascular Prevention & Rehabilitation. 2006;13(3):356-362.

(39) Sixt S, Rastan A, Desch S, Sonnabend M, Schmidt A, Schuler G, et al. Exercise training but not rosiglitazone improves endothelial function in prediabetic patients with coronary disease. European Journal of Cardiovascular Prevention & Rehabilitation. 2008;15(4):473-478.

(40) Theodorou AA, Panayiotou G, Volaklis KA, Douda HT, Paschalis V, Nikolaidis MG, et al. Aerobic, resistance and combined training and detraining on body composition, muscle strength, lipid profile and inflammation in coronary artery disease patients. Research in Sports Medicine. 2016;24(3):171-184.

(41) Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, Tanaka T, et al. Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease. PloS One. 2012;7(7):e41369.

(42) Vona M, Codeluppi GM, Iannino T, Ferrari E, Bogousslavsky J, von Segesser LK. Effects of different types of exercise training followed by detraining on endothelium-dependent dilation in patients with recent myocardial infarction. Circulation. 2009;119(12):1601-1608.

(43) Munk PS, Breland UM, Aukrust P, Ueland T, Kvaløy JT, Larsen AI. High intensity interval training reduces systemic inflammation in post-PCI patients. European Journal of Cardiovascular Prevention & Rehabilitation. 2011;18(6):850-857.

(44) Luk T, Dai Y, Siu C, Yiu K, Chan H, Lee SW, et al. Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial. European Journal of Preventive Cardiology. 2012;19(4):830-839.

(45) Jalaly L, Sharifi G, Faramarzi M, Nematollahi A, Rafieian-Kopaei M, Amiri M, et al. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 and E-Selectin in patients with stable angina pectoris. DARU Journal of Pharmaceutical Sciences. 2015;23(1):54.

(46) El Missiri A, Taher M. Effect of Phase 2 Cardiac Rehabilitation Program on High-Sensitivity C-Reactive Protein Levels in Post-Percutaneous Coronary Intervention Patients. J Cardiovasc Res. 2016;5:1, doi: http://dx.doi.org/10.4172/2324-8602.1000253

(47) Balen S, Vukelić-Damijani N, Peršić V, Ružić A, Miletić B, Samardžija M, et al. Anti-inflammatory effects of exercise training in the early period after myocardial infarction. Coll Antropol. 2008;32(1):285-291.

(48) Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc. 2011;43(7):1334-1359.

(49) Richardson M, Garner P, Donegan S. Interpretation of subgroup analyses in systematic reviews: A tutorial. Clinical Epidemiology and Global Health. 2018.

(50) Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among US adults. Epidemiology. 2002:561-568.

(51) Lin X, Zhang X, Guo J, Roberts CK, McKenzie S, Wu W, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association. 2015;4(7):e002014.

(52) Kelley GA, Kelley KS. Effects of aerobic exercise on C-reactive protein, body composition, and maximum oxygen consumption in adults: a meta-analysis of randomized controlled trials. Metab Clin Exp. 2006;55(11):1500-1507.

(53) Sloan RP, Shapiro PA, McKinley PS, Bartels M, Shimbo D, Lauriola V, et al. Aerobic exercise training and inducible inflammation: Results of a randomized controlled trial in healthy, young adults. Journal of the American Heart Association. 2018;7(17):e010201.

(54) Fedewa MV, Hathaway ED, Ward-Ritacco CL. Effect of exercise training on C reactive protein: a systematic review and meta-analysis of randomised and non-randomised controlled trials. Br J Sports Med. 2017;51(8):670-676.

(55) Al Shahi H, Shimada K, Miyauchi K, Yoshihara T, Sai E, Shiozawa T, et al. Elevated circulating levels of inflammatory markers in patients with acute coronary syndrome. International Journal of Vascular Medicine. 2015; doi: <u>https://doi.org/10.1155/2015/805375</u>

(56) Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.

(57) Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest. 2017;47(8):600-611.

(58) Sallam N, Laher I. Exercise modulates oxidative stress and inflammation in aging and cardiovascular diseases. Oxidative Medicine and Cellular Longevity. 2016; doi: http://dx.doi.org/10.1155/2016/7239639

(59) Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397.

(60) Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565.

(61) Kaptoge S, Di Angelantonio E, Lowe G, Pepys M, Thompson S, Collins R, et al. Emerging Risk Factors Collaboration C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140.

(62) Coppola G, Rizzo M, Abrignani MG, Corrado E, Di Girolamo A, Braschi A, et al. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. Ital Heart J. 2005;6(4):315-322.

(63) Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo, Jürgen CW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 1995;332(10):635-641.

(64) Ashor AW, Lara J, Siervo M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. Exercise modalities and endothelial function: a systematic review and dose–response meta-analysis of randomized controlled trials. Sports Medicine. 2015;45(2):279-296.

(65) Kawamura A, Miura S, Fujino M, Nishikawa H, Matsuo Y, Tanigawa H, et al. CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circulation Journal. 2003;67(10):851-854.

(66) Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28(11):1897-1908.

(67) Ostrowski K, Schjerling P, Pedersen BK. Physical activity and plasma interleukin-6 in humans–effect of intensity of exercise. Eur J Appl Physiol. 2000;83(6):512-515.

(68) Steensberg A, Van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol (Lond). 2000;529(1):237-242.

(69) Hayashino Y, Jackson JL, Hirata T, Fukumori N, Nakamura F, Fukuhara S, et al. Effects of exercise on C-reactive protein, inflammatory cytokine and adipokine in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Metab Clin Exp. 2014;63(3):431-440.

(70) Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. 2004;80(4):1029-1035.

(71) Albert MA, Danielson E, Rifai N, Ridker PM, Prince Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70.

(72) Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. Am J Cardiol. 2002;89(8):981-983.

(73) Kushner I, Broder ML, Karp D. Control of the acute phase response: serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978;61(2):235-242.

(74) Parkitny L, McAuley JH, Kelly PJ, Di Pietro F, Cameron B, Moseley GL. Multiplex cytokine concentration measurement: how much do the medium and handling matter? Mediators Inflamm. 2013;2013:890706.

(75) Lundman P, Boquist S, Samnegård A, Bennermo M, Held C, Ericsson C, et al. A high-fat meal is accompanied by increased plasma interleukin-6 concentrations. Nutrition, Metabolism and Cardiovascular Diseases. 2007;17(3):195-202.

(76) Gregersen S, Samocha-Bonet D, Heilbronn L, Campbell L. Inflammatory and oxidative stress responses to high-carbohydrate and high-fat meals in healthy humans. Journal of Nutrition and Metabolism. 2012; doi: http://dx.doi.org/10.1155/2012/238056

(77) Haykowsky MJ, Tomczak CR, Scott JM, Paterson DI, Kitzman DW. Determinants of exercise intolerance in patients with heart failure and reduced or preserved ejection fraction. J Appl Physiol. 2015;119(6):739-744.

(78) Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25(5):401-408.

# Table 1. Inclusion and exclusion protocol.

	Inclusion criteria		Exclusion criteria
•	Report published in English	•	Studies were excluded if a co-intervention was reported (i.e. provision of
•	Randomised trial		a hypocaloric diet or antioxidant/ vitamin supplement), to allow the
•	In consideration of standard treatment, studies involving control groups that		results to potentially reflect an independent effect of exercise
	routinely received usual care (i.e. pharmacological treatment and lifestyle	•	Studies that recruited CAD patients with severe heart failure (New York
	recommendations) were included		Heart Association Class III or IV or left ventricular ejection fraction $\leq$
•	Recruited only formally diagnosed coronary artery disease patients with		30%) were excluded to standardise the severity of CAD in the included
	history of a myocardial infarction, acute coronary syndrome, coronary		participants, along with the reduced exercise tolerance and increased
	revascularisation by percutaneous coronary intervention or coronary artery		inflammatory state associated with severe heart failure being potential
	by pass graft, or $\geq 50\%$ occlusion of at least one major coronary artery as		confounding variables (77,78)
	confirmed by an angiogram		
•	At least one inflammatory biomarker measured in blood (plasma or serum)		
	before and after an exercise intervention (any form of aerobic, resistance		
	training, or aerobic and resistance training combined) with a duration $> 2$ -		
	weeks, which may allow potential changes in inflammatory biomarkers to be		
	representative of exercise induced physiological adaptation		
•	Studies comprising exercise training in combination with a comprehensive		
	cardiac rehabilitation programme (i.e. lifestyle/ risk factor advice and		
	psychosocial management) were included if the additional components of the		
	programme were solely educational		

**Table 2.** GRADE system guidelines for rating overall quality of evidence (18).

GRADE Domain	Description							
Study Limitations	The quality of evidence is downgraded by the existence of internal limitations such as: lack of allocation concealment, lack of blinding, incomplete accounting of patients and outcome measures, selective outcome reporting, or terminating early for benefit.							
Inconsistency of Results	The quality of evidence is downgraded by the following criteria: wide variance of point estimates across studies, minimal or no overlap of confidence intervals, statistical tests for heterogeneity ( $\chi^2$ ) generate low P-values ( $\leq 0.1$ ), or large I <sup>2</sup> values are documented.							
Indirectness of Evidence	The quality of evidence is downgraded if interventions were not compared directly to one another, or if a restricted version of the main review question in terms of population, intervention, or outcomes was investigated.							
Imprecision	The quality of the evidence is downgraded when studies included relatively few participants and thus had wide confidence intervals around the estimate of effect.							
Publication Bias	The quality of the evidence is downgraded if a systematic under-estimation or an over- estimation of significant or non-significant intervention effects due to the selective publication of studies is suspected.							



Figure 1. PRISMA flow diagram depicting the study selection process.

		Ex	ercise		C	ontrol			Std. Mean Difference	Std. Mean Difference
	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ī	1.1.1 CRP									
	Balen et al. (2008)	5.67	4.67	30	13.33	6.23	30	7.5%	-1.37 [-1.94, -0.81]	_ <b></b>
	Bilińska et al. (2010)	0.19	0.23	59	0.3	0.61	59	8.3%	-0.24 [-0.60, 0.13]	
	Fernandes et al. (2011)	1.5	2.59	15	1.5	1.85	19	7.0%	0.00 [-0.68, 0.68]	<del></del>
	Giallauria et al. (2011)	3.9	1.8	37	13.4	3.9	38	7.0%	-3.08 [-3.76, -2.40]	
	Lee et al. (2012)	0.08	0.16	22	0.23	0.65	24	7.5%	-0.31 [-0.89, 0.28]	<b>-</b> _
	Lian et al. (2014) [Evening CAE]	2.36	0.79	64	3.2	0.86	39	81%	-1 02 [-1 44 -0 60]	_ <b>_</b>
	Lian et al. (2014) [Morning CAE]	2.00	0.86	70	3.2	0.86	38	8.2%	-0.50[-0.90]-0.10]	
	Madssen et al. (2014)	1.07	0.00	24	1.5	2.5	25	7.6%	-0.23[-0.79]0.33]	<del></del>
	Ribeiro et al. (2014)	1.01	1 /1	27	n.0	n 90	20	7 3 96	0.23[0.73,0.33]	
	Schumacher et al. (2012)	2.22	1.72	95	282	2.61	20 Q/	2.5%	-0.20[-0.20, 0.34]	
	Schumacher et al. (2000) Sixt at al. (2000)	2.23	1.75	10	2.00	2.01	10	0.0.0	-0.20 [-0.43, 0.00]	
	Theodorou of al. (2016) [ALE & DTL	0.20	0.0	15	0.4	0.05	5	0.3 /0 E E 0/.	0.33[1.22, 0.43]	
	Theodorou et al. (2016) [AIE & RT]	0.20	0.02	10	0.4	0.00	5	0.0% 5.50%	-0.17 [-1.10, 0.04]	
	Theodorou et al. (2016) (AlE)	0.28	0.54	10	0.4	0.85	2	5.5%	-0.18[-1.20, 0.83]	
	Ineodorou et al. (2016) [R1]	0.32	0.53	11	0.4	0.85	5	5.4%	-0.12[-1.18, 0.94]	
	Subtotal (95% CI)			49Z			411	100.0%	-0.55 [-0.95, -0.16]	-
	Heterogeneity: Tau <sup>2</sup> = 0.43; Chi <sup>2</sup> = 88	3.46, df =	: 13 (P	< 0.00	001); I <sup>z</sup> a	= 85%				
	Test for overall effect: Z = 2.79 (P = 0	.005)								
	1.1.2 Fibrinogen									
	Balen et al. (2008)	4.3	1.2	30	5.3	1.8	30	15.2%	-0.65 [-1.17, -0.13]	
	Bilińska et al. (2010)	3.53	0.89	59	4.17	1.37	59	25.3%	-0.55 [-0.92, -0.18]	
	Lian et al. (2014) [Evening CAE]	0.93	0.19	89	1.08	0.19	49	25.9%	-0.79 [-1.15, -0.42]	
	Lian et al. (2014) [Morning CAE]	1.04	0.15	89	1.08	0.19	48	26.7%	-0.24 [-0.59, 0.11]	
	Sixt et al. (2008)	3.6	0.5	13	3.7	0.8	10	6.9%	-0.15 [-0.97, 0.68]	
	Subtotal (95% CI)			280			196	100.0%	-0.52 [-0.74, -0.29]	◆
	Heterogeneity: $Tau^2 = 0.02$ ; $Chi^2 = 5$	50 df=-	4 (P = 1	1 24) <sup>,</sup> P	<sup>2</sup> = 27%					
	Test for overall effect: $7 = 4.43$ (P < 0	00001)	. (.							
	1.1.3 vWF									
	Munketal (2011)	aa a	61.2	18	173.2	146.4	18	24.5%	-0.64 [-1.31_0.03]	_ <b>_</b>
	Vona et al. (2011)	Q1	11	53	100.2	15	17	24.0%	-1 / 8 [-7 08 -0 87]	_ <b>_</b>
	Vona et al. (2003) [CAE]	00 20	9.0	52	103	15	17	23.370	-7.17[-2.00,-0.07]	_ <b>_</b>
	Vona et al. (2003) [CAL]	00	0.0	54	103	15	16	24.770	-2.17 [-2.05, -1.51]	
	Subtotal (95% CI)	07	9.4	177	109	10	68	24.9%	157[223 002]	-
	Historegeneity Tey 2 - 0.24: Chi2 - 41	0.00 df_	а (п. –	0.007	12 - 70	· 0/	00	100.070	-1.57 [-2.25, -0.52]	•
	Test for success 4 offers 7 4 74 (D + 0	2.26, ui =	3 (P =	0.007	), = 76	170				
Lest for overall effect: $z = 4.71$ (P < 0.00001)										
	44486									
	1.1.4 IL-0									
	Bilińska et al. (2010)	2.25	1.61	59	2.77	2.27	59	24.2%	-0.26 [-0.62, 0.10]	
	Munk et al. (2011)	0.61	0.39	18	1.13	0.55	18	12.5%	-1.07 [-1.77, -0.36]	
	Oliveira et al. (2015)	1.2	0.77	44	1.53	1.77	42	21.5%	-0.24 [-0.67, 0.18]	
	Ribeiro et al. (2012)	3.1	2.15	20	3.3	1.41	18	14.2%	-0.11 [-0.74, 0.53]	
	Schumacher et al. (2006)	3.3	2.42	95	3.12	2.06	94	27.7%	0.08 [-0.21, 0.36]	
	Subtotal (95% CI)			236			231	100.0%	-0.24 [-0.55, 0.07]	•
	Heterogeneity: Tau <sup>2</sup> = 0.07; Chi <sup>2</sup> = 9.	57, df = -	4 (P = I	0.05); P	<b>²</b> = 58%					
	Test for overall effect: Z = 1.54 (P = 0	.12)								
	1.1.5 TNF-alpha									
	Balen et al. (2008)	45.77	44.6	30	37.4	18.14	30	16.1%	0.24 [-0.27, 0.75]	- <b>+</b>
	Munk et al. (2011)	1.3	0.95	18	1.32	0.55	18	9.7%	-0.03 [-0.68, 0.63]	<b>_</b>
	Oliveira et al. (2015)	7.4	3.16	44	7.83	3.84	42	23.2%	-0.12 [-0.54 0.30]	_ <b>_</b>
	Schumacher et al. (2006)	3.08	1.83	95	3.57	2.89	94	50.9%	-0.20 [-0.49 0.08]	
	Subtotal (95% CI)	0.00		187	0.01	2.00	184	100.0%	-0.09 [-0.30. 0.11]	
	Heterogeneity: $Tau^2 = 0.00$ ; $Cbi^2 = 2$	29 df-1	3 (P = 1	1.511-8	² = 0%					٦
	Test for overall effect: $7 - 0.01 / P - 0$	20, ar 36)			- 0 /0					
	163101 0/61411 6186L Z = 0.31 (F = 0	.50)								
										-4 -2 0 2 4
										Favours [Exercise] Favours [Control]

Figure 2.1. Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

*Key: SD* standard deviation, *Std* standardised, *IV* inverse variance, *CI* confidence interval, *CRP* C-reactive protein, *vWF* von Willebrand factor, *IL-6* interleukin-6, *TNF-alpha* tumour necrosis factor-alpha, *CAE* continuous aerobic exercise, *AIE* aerobic interval exercise, *RT* resistance training



**Figure 2.2.** Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

*Key: SD* standard deviation, *Std* standardised, *IV* inverse variance, *CI* confidence interval, *ICAM-1* intercellular adhesion molecule-1, *VCAM-1* vascular cell adhesion molecule-1



Figure 2.3. Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

*Key: SD* standard deviation, *Std* standardised, *IV* inverse variance, *CI* confidence interval, *IL*-8 interleukin-8, *RANTES* regulated on activation, normal T-cell expressed and secreted

	Ex	ercise	•	Control				Std. Mean Difference		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% CI	
1.2.1 IL-10											
Balen et al. (2008)	4.07	2.02	30	3.67	3.11	30	27.3%	0.15 [-0.36, 0.66]			
Munk et al. (2011)	1.93	1.6	18	1.62	1.06	18	16.3%	0.22 [-0.43, 0.88]			
Oliveira et al. (2015)	8.47	5.75	44	9.7	7.68	42	39.1%	-0.18 [-0.60, 0.24]			
Ribeiro et al. (2012)	7	8.15	20	6.7	4	18	17.3%	0.04 [-0.59, 0.68]			
Subtotal (95% CI)			112			108	100.0%	0.01 [-0.25, 0.28]		<b>•</b>	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.49, df = 3 (P = 0.69); l <sup>2</sup> = 0%											
Test for overall effect: Z = 0.11 (P = 0.91)											
									-2	-1 0 1 2	
									-	Favours [Control] Favours [Exercise]	

**Figure 3.** Forest plot of post-intervention IL-10 value comparison between exercise and control groups.

*Key: SD* standard deviation, *Std* standardised, *IV* inverse variance, *CI* confidence interval, *IL-10* interleukin-10



Figure 4. Review authors' judgements about each risk of bias item for each included study.

# List of figure captions.

Figure 1. PRISMA flow diagram depicting the study selection process.

**Figure 2.1.** Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

**Figure 2.2.** Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

**Figure 2.3.** Forest plots of post-intervention inflammatory biomarker value comparisons between exercise and control groups.

Figure 3. Forest plot of post-intervention IL-10 value comparison between exercise and control groups.

Figure 4. Review authors' judgements about each risk of bias item for each included study.